R ecent exposure to drug-drug interactions (DDIs) is associated with an increased risk for hospitalization for adverse drug events.
R ecent exposure to drug-drug interactions (DDIs) is associated with an increased risk for hospitalization for adverse drug events.
1,2 DDI-related preventive measures used to improve patient safety include screening and decision support within electronic prescribing and pharmacy information systems. Pharmacy benefit managers (PBMs) also implement quality measures to improve patient safety, with online and retrospective drug utilization review (DUR) interventions that alert clinicians of potential DDIs (PDDIs).
PBMs process a large proportion of prescriptions in the United States and frequently detect the dispensing of prescription medications known to interact. Solberg et al. (2004) analyzed prescription drug claims data from 2 large health plans and estimated that the frequency of PDDIs range from 6.2% to 6.7% per year. 3 Malone et al. (2005) analyzed prescription drug claims data during a 25-month period and found that an estimated 374,000 participants were exposed to clinically important DDIs out of nearly 46 million plan participants. 4 Lafata et al. (2006) found that 17.8% to 28.0% of the 67,820 insured adults who were dispensed specific medications (warfarin, digoxin, cyclosporine, or lovastatin/simvastatin) concomitantly received an interacting drug. 5 In 2012, Phansalkar et al. developed a list of high-priority PDDIs to be considered
• Recent exposure to drug-drug interactions is associated with an increased risk for hospitalization for adverse drug events.
• Clinician alert fatigue may occur with processes that send many drug-drug interactions messages, especially involving low-risk interactions.
• Drug-drug interaction references do not always agree with rating the severity of drug-drug interactions.
What is already known about this subject
• 42.6% of respondents agreed or strongly agreed that fax alerts were a good way to communicate with them. However, 37.5% of respondents either agreed or strongly agreed that the fax alert was a "waste of my time." • Some prescribers valued fax alerts, especially for less well-known potential drug-drug interactions.
What this study adds

■■ Methods
This was a prospective cross-sectional study in which a PBM distributed evidence-based information about 18 different PDDI pairs that included evidence summaries and suggested management strategies. The alerts were faxed the following morning (i.e., near real time) to the prescriber of the second drug of the PDDI that included an evidence-based summary of the PDDI along with a 16-item questionnaire. Prescribers were requested to complete and fax back the questionnaire. The respondents received no payment for participating in the study. The project was approved by the University of Arizona Human Subjects Protection Program.
Interacting Drugs
Eighteen drug interactions considered by the authors to be clinically important were selected for the fax alerts ( Table 1) . The interactions were identified and evaluated based on previous research on DDI evidence using a modified Delphi method, 10 supporting documentation identified (i.e., primary literature, product labeling, and compendia), [11] [12] [13] [14] [15] [16] potential clinical consequences, frequency of coprescription, 4 input from the for intervention as well as low-priority PDDIs that were safe to suppress from interruptive alerting in electronic health records. 6, 7 These Phansalkar studies were published after the data were collected for the current study and have some differences in recommendations regarding PDDIs for future software with electronic alerts for PDDIs.
Retrospective DUR programs that communicate drugrelated problems to prescribers by fax or mail are common in managed care, although few controlled studies evaluating the effect of these interventions have been conducted. 8 Further evaluation of the quality of these interventions in terms of prescriber perception and satisfaction also is needed. 8 With this background, the present study was designed in collaboration with a large national PBM (MedImpact Healthcare Systems, Inc.) to assess the usefulness of a PDDI fax alert intervention. The purpose of this study was to (a) determine if prescribers are aware of the PDDI described in individualized fax alerts, and (b) evaluate prescriber attitudes and satisfaction with the intervention process. Results evaluating the influence of the fax-alert program on prescribing were reported separately. 
TABLE 1
Potential Drug-Drug Interactions Selected for Fax Alert Intervention
clinicians employed by the PBM, and the previous experience of MedImpact from a prior fax-alert program for DDIs. An evidence-based summary was developed for each of the 18 interactions following a review of peer-reviewed literature, relevant product labeling, drug compendia, and reputable online resources. The researchers also provided suggested management strategies (i.e., consider prescribing an alternative drug, monitor the patient, and/or educate the patient) for each PDDI.
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Data Source
Through collaboration with MedImpact Healthcare Systems, Inc., 2 health plans participated in the study. One health plan was a large managed care organization (~500,000 members) and the second health plan was a managed Medicaid plan (180,000 members). For the Medicaid plan, the program only targeted in-network providers. Computer algorithms were developed and ran daily to identify PDDIs of interest. When a PDDI was identified, a fax alert was generated and sent to the prescriber of the interacting drug (i.e., second prescription claim) on the following day. The fax alert included a cover letter introducing the study, a clinical monograph evaluating the strength of evidence for the PDDI, and a questionnaire. Prescribers were asked to complete the questionnaire and fax their responses back for data entry. One health plan used all 18 PDDIs, and the second health plan used 17 PDDI pairs of interest. The benzodiazepine-azole antifungal PDDI was excluded by the second plan because of state regulatory concerns. Completion of the questionnaire by prescribers was voluntary.
The questionnaire consisted of 16 questions (Appendix, available in online article). Face validity by the study authors was used to assess the questionnaire. Prescribers were asked to confirm whether the patient was their patient, indicate whether they were aware the patient was taking both medications, whether they were aware of the interaction, and if any action was planned after receiving the fax alert. In addition, prescribers were asked how many patients they saw per day, their gender, and whether they thought the fax alert was a waste of time. Prescribers also were asked whether fax alerts were a good way to communicate with them, whether they would prefer a telephone call about PDDIs, and if their computer system already provided them with information about drug-drug interactions.
Time Period
The fax alert intervention, in which PDDIs of interest were identified and fax alert messages were sent, was implemented for a total of 6 months, from May 2010 to November 2010. Survey responses were collected for 2 months following the conclusion of the intervention for analysis.
Selection Criteria
Patient and prescriber characteristics were assessed for each PDDI pair. The fax alert program was based on the PDDIs of interest that allowed prescribers to be targeted more than once if the prescriber had prescribed an interacting agent for more than 1 patient and/or multiple PDDIs for the same patient.
Prescriber specialties were identified for prescribers who received a fax alert based on Health Market Science data (updated January 2011) containing self-reported specialties. Because a practitioner may have multiple specialties, the primary specialty listed was used.
The statistical analysis consisted of calculating mean scores and standard deviations for those questions considered to be measured on at least an ordinal scale (e.g., Likert-type questions). Chi square tests were used to assess for differences in proportions among survey respondents and patient characteristic categories. Multivariate logistic regression was used to assess factors associated with respondents returning a completed questionnaire. The outcome variable of interest was whether a questionnaire response was received. Confounding variables included patient age group; patient gender; prescriber specialty (i.e., primary care vs. specialist); practitioner type (i.e., physician, nurse practitioner, physician assistant, or other health care professional); acute medication; and First DataBank 
■■ Results
The demographic characteristics of patients for whom a PDDI was identified are summarized in Table 2 . Two-thirds (66%) of fax alerts sent were for patients at least aged 65 years. PDDIs were uncommon in patients less than aged 40 years (3%). Women represented 53.2% of PDDIs. Between the 2 health plans participating in the study, patients enrolled in commercial insurance represented 87.7% of PDDIs. A total of 8,075 fax alerts were distributed, and 977 questionnaires were Table 4 summarizes the number of unique fax alerts and questionnaire responses by PDDI category. The most common PDDI pairs were for warfarin-statin (3,511, 43.5%) and warfarin-thyroid (2,111, 26.1%) interactions. Completed questionnaires regarding these 2 interactions comprised the largest number of questionnaire responses from prescribers as well.
A total of 948 (97%) prescribers responded that the patient with the identified PDDI was their patient. Across all PDDIs, 96% of respondents indicated they were aware that the patient was taking both medications. Eighty-one percent of respondents indicated they were aware of the PDDI, and 49% indicated they had educated the patient about the PDDI.
In response to the fax alerts, 62% of respondents indicated they planned to do "nothing"; 15% indicated they planned to order a serum drug level or other laboratory test; 13% planned to educate the patient; 5% planned to discontinue 1 of the medications; and 2% planned to switch and initiate a new medication.
It was noted that 42.6% of respondents agreed or strongly agreed that fax alerts were a good way to communicate with them. However, 37.5% of respondents either agreed or strongly agreed that this specific fax was a "waste of my time." There were 59.1% of respondents who either disagreed or strongly disagreed that they would prefer to receive a telephone call when interactions like this occur. In addition, there were 50.5% of respondents who indicated that their computer system currently provided them with at least some DDI alert information.
When the prescriber attitudes toward the fax alert were stratified by PDDI pair, some differences were noted. For example, in responding to the question that this fax was a "waste of my time," respondents disagreed or disagreed strongly when 
TABLE 4
Counts of Unique Fax Alerts Sent and Questionnaire Response Rates
they received the carbamazepine-macrolide (mean 1.5 ± 0.71), ciprofloxacin-tizanidine (mean 2.3 ± 1.0), and statin-macrolide (mean 2.3 ± 1.1) fax alert information. In contrast, respondents agreed or strongly agreed that the fax alert was a "waste of time" when they received the isotretinoin-tetracycline/minocycline (mean 4.5 ± 1.0) information. The ciprofloxacin-tizanidine and statin-macrolide PDDI pairs were also included in the Phansalkar et al. list of critical PDDIs. 7 Multivariate logistical regression analyses were conducted to examine the characteristics associated with whether prescribers returned a questionnaire response (Table 5 ). In examining all PDDIs, prescribers who had previously received a fax alert were less likely to respond to the questionnaire compared with prescribers receiving 1 questionnaire (odds ratio [OR] 0.685, 95% confidence interval [CI] 0.584-0.804) controlling for acute medications, patient gender, FDB PDDI severity rating, and patient age. Controlling for these same independent variables, specialists were less likely to respond to the questionnaire compared with primary care prescribers (OR 0.851, 95% CI 0.742-0.975).
■■ Discussion
This study was conducted because there has been limited research about the quality of previous interventions for drug therapy problems in terms of prescriber perception and satisfaction. Prescriber perceptions of the usefulness of evidencebased PDDI fax alerts are a reflection of the drug combination for which the alert is based. Study results found that fax alerts for interactions of carbamazepine-macrolide, ciprofloxacintizanidine, and statin-macrolide were perceived as being more valuable by respondents. This may indicate that prescribers were less familiar with the evidence supporting these PDDIs. It is possible that the isotretinoin interaction was scored as less valuable by respondents because isotretinoin may be prescribed by specialists (i.e., dermatologists) or other clinicians focused on treating acne who were previously aware of the interaction with tetracycline antibiotics. Furthermore, the evidence to support this interaction is limited to sporadic case reports, and the clinical importance of this PDDI in product labeling may be overstated. 18, 19 In addition, many patients are discontinued from antibiotic therapy and are treated with isotretinoin (which is used for severe or recalcitrant acne and is often considered the last resort). Additionally, isotretinoin therapy requires that prescribers are certified to prescribe this agent, and there is a very intensive risk evaluation and mitigation (REM) strategies program (iPLEDGE) that is involved with the prescribing and dispensing of isotretinoin. This DDI may not have been considered very useful, since the prescribing is already very tightly managed.
The nitrate-PDE5 inhibitor interaction is widely known, likely based on extensive discussion in both professional and lay media. 20, 21 Concurrent use of nitrates and PDE5 inhibitors is contraindicated based on reports of myocardial infarction and fatalities, with clinical studies showing additive hypotensive effects. [22] [23] [24] [25] [26] However, some published reports have questioned these safety concerns, and there may be divergence between the risks stated in product labeling and drug compendia compared with the perceived clinical importance by prescribers. 27, 28 Regardless, recipients were likely already aware of the PDDI, so the information provided in the fax alert was considered less useful.
The respondents indicated that in 96% of cases, patients were indeed receiving both medications identified in the fax alert. However, it is important to note that approximately 80% of the respondents indicated they were already aware of the PDDI. This finding is in contrast to studies showing poor prescriber knowledge of DDIs. 20, 29 For example, results from a national survey found that fewer than half of the prescriber participants were able to identify clinically important DDIs. 20 In addition, it is an interesting question whether to inquire about differences between different age ranges of physicians. Possibly younger physicians with less experience may find the fax alerts (or electronic alerts) more useful than experienced clinicians.
In response to the evidence-based information about the PDDI, almost two-thirds of respondents indicated that no action was necessary. Prescribers may have felt they were already aware of the evidence or that the risk of complications 
■■ Conclusions
Retrospective DUR programs to notify prescribers of PDDIs are commonly used by PBMs as part of their patient safety efforts. The majority of prescribers responding to a PDDI fax alert survey indicated they were already aware of specific PDDIs, and approximately half indicated that they had computer access to DDI information. Some specific PDDI pairs were considered more valuable (e.g., carbamazepine-macrolide, ciprofloxacintizanidine, and statin-macrolide) compared with medications commonly prescribed by specialists (e.g., isotretinoin-tetracycline/minocycline) or PDDIs that are so widely discussed in public and professional domains that they are essentially common knowledge (e.g., nitrate-PDE5 inhibitor). Distribution of focused, evidence-based PDDI information is encouraged for carefully selected PDDIs. was low. There were 5% of prescribers that planned to have the patient stop 1 of the medications involved in the PDDI, and 2% reported they would switch therapy and initiate a new medication.
Some research has been conducted related to prescriber perspectives about electronic DDI alerts. Although prescribers are generally supportive of drug safety alerts in concept, there is dissatisfaction with certain aspects of alerting systems. [29] [30] [31] In a survey by Weingart et al. (2009) , more than half of prescribers were dissatisfied with e-prescribing DDI or allergy alerts, noting problems such as alerts triggered by medications patients were no longer taking, alerts failing to account for appropriate drug combinations, and an excessive volume of alerts. 31 Clinicians have a strong preference about receiving recommendations in addition to the assessments in drug safety alerts. 30, 32, 33 Overall, the effectiveness of different approaches on the design and display of alerts has largely not been evaluated. 34 The literature also indicates inconsistent performance of DDI screening software used in electronic prescribing and pharmacy information systems. 35, 36 Another interesting issue to consider is the use of communicating alerts through mobile devices such as tablets and mobile "smart" phones. Although faxes are common now, they may become antiquated, and electronic alerts may become more common. Attention to DDI alerts by prescribers and pharmacists also is a challenge. 32, 37 Therefore, this study supports that improved health system interventions are greatly needed to minimize patient exposure to potentially harmful drug combinations or to mitigate risk when coadministration of interacting drug pairs is considered necessary.
Limitations
There are several important limitations with this study. PDDIs primarily associated with drugs requiring intensive REM monitoring (e.g., isotretinoin-minocycline/tetracycline) or commonly known PDDIs (e.g., nitrate-PDE5 inhibitor) may have been less useful choices because these drugs are more commonly prescribed by specialists. Another limitation of this analysis was a small sample size because of the low prevalence of some PDDIs. In addition, the frequency of fax alerts for 2 PDDIs (warfarin-statin and warfarin-thyroid hormone therapy) were much higher than others and may have biased the overall results. Because individual prescribers could have received information more than once, this may have adversely impacted the respondents' value of the PDDI information provided. In addition, the level of prescriber reimbursement may have played a role in the willingness to respond to the questionnaire. Lastly, the results of this study should not be generalized beyond those prescribers who returned a questionnaire. While the response rate in the study is better than some prescriber surveys, it is difficult to draw definitive conclusions from this study for all prescribers who received at least 1 fax alert.
